как спастись от блевантина?

[Sixteen]

Вот тут в другой моей теме про круиз была поднята тема
блевантина. У меня его обычно не бывает, но если сильная качка будет,
то все может случиться. Что тогда делать? Как спастись от блевантина?
А то он испортит весь круиз!

[Дядя_Федор]

У меня вот тоже морская болезнь.
Так я и не плаваю никогда... ;)

[Akela]

Вот тут в другой моей теме про круиз была поднята тема
блевантина. У меня его обычно не бывает, но если сильная качка будет,
то все может случиться. Что тогда делать? Как спастись от блевантина?
А то он испортит весь круиз!

Dramamine.

[Malishka]

Вот тут в другой моей теме про круиз была поднята тема
блевантина. У меня его обычно не бывает, но если сильная качка будет,
то все может случиться. Что тогда делать? Как спастись от блевантина?
А то он испортит весь круиз!

Ask for a prescription for SCOPOLAMINE PATCH. It's pretty strong!

[nat123]

Я уже писала где-то, мне морак бывший на яхте в шторм сказал - выпей рюмку водки, мозжечёк отключится и всё будит хорошо. Я думала, что если при этих ташнотиках ещё и водки, то я умру. Но ничё настроилася - выпила и фсё как рукой сняло. Токо напиваться нельзя, одну румочку и усё. Почему водки,а не вина тама, я не знаю, моряцкая тайна наверное...но мож ромом можна заменить?

[Sixteen]

Ask for a prescription for SCOPOLAMINE PATCH. It's pretty strong!

раз он такой сильный, то какии ат нево сайд эффекты?
небось вызываит импотенцыю и головную боль и сильный понос?

[Malishka]

раз он такой сильный, то какии ат нево сайд эффекты?
небось вызываит импотенцыю и головную боль и сильный понос?

Motion sickness: 1 transdermal PATCH behind ear 4 hr before needed, replace every 3 days if needed

Adverse Effects

COMMON
Gastrointestinal: Xerostomia
Neurologic: Somnolence
Ophthalmic: Blurred vision
SERIOUS
Cardiovascular: Alteration in heart rate, Transient
Psychiatric: Drug-induced psychosis (rare)

[Malishka]

Я тебе покажу сейчас ПОЛНЫЙ профаил, но вчитайся, большинство проблем у пожилых или у тех у кого уже есть существующие проблемы, ок?

Adverse Reactions

3.3.1 Cardiovascular Effects

3.3.1.A Cardiac dysrhythmia
1) TACHYCARDIA is common after treatment with scopolamine especially with higher doses (Sifton, 1998; Gilman et al, 1980b). At low doses (0.1 to 0.2 mg), scopolamine produces cardiac slowing which is greater than observed with atropine (Gilman et al, 1980b).


3.3.1.B Hypotension
1) Hypotension has been reported during scopolamine therapy in combination with morphine. Hypotension was reported in 38% of 201 patients receiving scopolamine (up to 2.5 mg SC as a single dose) in combination with morphine when administered as a premedicant for abdominal surgery with cyclopropane anesthesia (Kristoffersen & Clausen, 1967).


3.3.2 Dermatologic Effects

3.3.2.A Dermatological finding
1) RASHES and ERYTHEMA have been reported during use of transdermal scopolamine (Prod Info Transderm Scop(R), 1999). Of 68 patients who used transdermal scopolamine to prevent motion sickness, 4.4% discontinued treatment due to CONTACT DERMATITIS (Shupak et al, 1989).

3.3.4 Gastrointestinal Effects

3.3.4.A Gastrointestinal tract finding
1) DRY MOUTH (XEROSTOMIA) is the most common adverse effect associated with scopolamine (Prod Info Scopolamine, 1998)(Prod Info Transderm Scop(R), 1999; Clissold & Heel, 1985a; Wood & Graybiel, 1972; Giovanelli & Vigo, 1970); (Brand & Whitingham, 1970). CONSTIPATION may also occur during treatment with scopolamine (Sifton, 1998).


3.3.9 Neurologic Effects

3.3.9.A Central nervous system finding
1) At higher doses, scopolamine may cause DIZZINESS, RESTLESSNESS, TREMORS, FATIGUE, and locomotor difficulty (Prod Info Scopolamine, 1998). Transdermal scopolamine may also cause DROWSINESS, RESTLESSNESS, MEMORY DISTURBANCES, HALLUCINATIONS, and CONFUSION (Prod Info Transderm Scop(R), 1999; Johnson et al, 1984). Irritability, disorientation, confusion, hallucinations, and tremor occur more frequently in children than adults (Wilkinson, 1987).
2) A 38-year-old woman developed agitation, confusion, and a dilated right pupil after using a scopolamine patch for nausea and vomiting associated with epidural analgesia (Elias & Abouleish, 1997). Symptoms occurred about 2 hours after the scopolamine patch was removed. Pilocarpine 1% eye drops were instilled in both eyes; however, only the left eye constricted. Since the symptoms were likely induced by scopolamine, physostigmine 0.5 mg was administered to a total dose of 1.5 mg, and all symptoms were rapidly reversed. Within 12 hours, the patient was alert and both pupils were of normal size. Most cases of scopolamine-induced dilated pupil occur in the eye on the same side as the patch. The etiology may be related to inadvertent transfer of drug from the patch to eye by the hand or absorption of drug into the internal carotid artery and the ophthalmic artery.
3) Overdosage of scopolamine has been associated with acute toxic psychosis (Ullman & Groh, 1972; Bernstein & Leff, 1967) and SCHIZOPHRENIC REACTIONS (Ullman & Groh, 1972).


3.3.9.B Coma
1) Deep coma and MENINGISM were described in a 52-year-old female following premedication with scopolamine 0.4 mg IM, hydroxyzine 50 mg IM and meperidine 100 mg IM for a pancreatoduodenectomy. (Samuels & Washington, 1980). Following administration, the patient was deeply comatose and marked nuchal RIGIDITY was noted. Naloxone produced little change in level of consciousness, and physostigmine 1 mg IV had no effect. A second dose of physostigmine 1 mg IV administered 10 minutes later produced a dramatic effect, with the patient awakening and becoming alert and oriented. Deep tendon reflexes and Babinski responses returned to normal and no rigidity was observed. The authors suggest that since the patient had abnormal liver function prior to the episode as well as low serum albumin levels, this may have combined synergistically with hydroxyzine and meperidine to contribute to the profound CNS depression and coma. Since the patient did not respond to naloxone, meperidine probably had no effect on muscle rigidity, and the most likely cause of meningismus was scopolamine.


3.3.10 Ophthalmic Effects

[Malishka]

3.3.10.A Anisocoria
1) A 38-year-old woman developed agitation, confusion, and a dilated right pupil after using a scopolamine patch for nausea and vomiting associated with epidural analgesia (Elias & Abouleish, 1997). Symptoms occurred about 2 hours after the scopolamine patch was removed. Pilocarpine 1% eye drops were instilled in both eyes; however, only the left eye constricted. Since the symptoms were likely induced by scopolamine, physostigmine 0.5 mg was administered to a total dose of 1.5 mg, and all symptoms were rapidly reversed. Within 12 hours, the patient was alert and both pupils were of normal size. Most cases of scopolamine-induced dilated pupil occur in the eye on the same side as the patch. The etiology may be related to inadvertent transfer of drug from the patch to eye by the hand or absorption of drug into the internal carotid artery and the ophthalmic artery.
2) Anisorcoria was described in a 25-year-old woman during scopolamine patch use. The patient presented with an enlarged left pupil, drowsiness and diarrhea of 1 day's duration and the diagnosis of intracranial neoplasm or aneurysm was considered. A scopolamine patch was located behind the left ear for prophylaxis against motion sickness, and anisocoria subsided over the next 4 hours as well as other symptoms. The patient inadvertently transferred scopolamine into her left eye by contact from her finger after application of a scopolamine patch (Price, 1985).
3) Anisocoria was described in a 27-year-old woman secondary to application of a scopolamine patch behind the left ear to prevent motion sickness (Rosenberg, 1987). The patient presented with a dilated, 6 mm left pupil that failed to contrict with light. The patient had applied the scopolamine patch 7 days previously and had not removed it. Patch removal resulted in normalization of the pupil response over the next 2 hours.


3.3.10.B Esotropia
1) A 4-year-old boy who was treated with one-fourth of a transdermal scopolamine patch 1.5 mg every 3 days for drooling developed esotropia (eg, CROSS-EYE or CONVERGENT STRABISMUS) within five days of starting treatment. Following a complete ophthalmic examination which identified esotropia, the transdermal scopolamine patch was stopped at the recommendation of the ophthalmologist. At a follow-up ophthalmic examination one month after stopping the transdermal scopolamine patch, abnormalities related to accommodation were absent. Rechallenge was not performed. The authors postulated that systemic anticholinergic effects of scopolamine were sufficient to induce esotropia. Since use of transdermal scopolamine is common in children with developmental disabilities and excessive drooling, clinicians should be aware of this possible adverse effect (Good & Crain, 1996).


3.3.10.C Eye / vision finding
1) Adverse effects associated with long-term use of the ophthalmic product include local IRRITATION which is described as CONJUNCTIVITIS, vascular CONGESTION, EDEMA, and eczematous dermatitis. In addition, VISUAL HALLUCINATIONS may occur (Sifton, 1998).
2) Systemic scopolamine products cause MYDRIASIS which results in BLURRED VISION and PHOTOPHOBIA. At higher doses, CYCLOPLEGIA has also been reported (Sifton, 1998; Clissold & Heel, 1985a; Novak & Probst, 1973; Giovanelli & Vigo, 1970); (Brand & Whitingham, 1970). Transdermal scopolamine may cause dry, red, or itchy eyes and acute narrow-angle GLAUCOMA (Prod Info Transderm Scop(R), 1999).
3) A 20-year-old female on vacation in Mexico was noted to have a UNILATERAL DILATED PUPIL. History revealed no familial aneurysms, no head trauma, no nuchal rigidity, and no visual defect in that eye. It was noted, however, that the patient removed a Transderm-Scop(R) disc the evening before and had also removed her contact lenses. It was therefore concluded that the patient either touched her eye or contaminated her soft contact lenses which were reinserted in the morning. It is therefore stressed that patients handle the Transderm-Scop(R) disc carefully, wash hands following application or removal, and avoid contact with the eyes (Carlston, 1982).


3.3.12 Psychiatric Effects

3.3.12.A Psychotic disorder
1) Although transdermal scopolamine was thought to obviate most symptoms associated with other forms of scopolamine, psychosis developed in a 71-year-old female. The patient became psychotic, agitated and paranoid, complained of visual hallucinations and experienced tachycardia and mydriasis within 3 days of application of a Transderm-Scop(R) disc. The patient was also receiving propranolol, isosorbide, digoxin, furosemide and meclizine. It is possible that the psychotic reaction was caused by combination of scopolamine and meclizine. Haloperidol 2 mg IM did not improve behavior. The transdermal disc was removed and the patient received physostigmine salicylate 1 mg IM and within 3 hours psychotic symptoms, tachycardia, and cycloplegia resolved (Osterholm & Camorano, 1982). Psychosis has been reported by other authors following the use of transdermal scopolamine (Ziskind, 1988; Mego et al, 1988; Rodysill & Warren, 1983).
2) TOXIC PSYCHOSIS was reported in a 67-year-old woman who received eyedrops containing atropine 0.02 g/mL, scopolamine 5 mg/mL and phenylphrine 40 mg/mL (Kortabarria et al, 1990). The patient received 6 to 8 drops of this preparation in each eye for ophthalmologic laser therapy. The onset of symptoms was sudden. In addition, the symptoms reappeared after rechallenge. The psychotic symptoms were similar to those induced by atropine.


3.3.13 Renal Effects

3.3.13.A Dysuria
1) Scopolamine may cause difficulty in urinating and URINARY RETENTION; this adverse effect is especially bothersome in elderly patients and older men with prostatic hypertrophy (Prod Info Scopolamine, 1998)(Prod Info Transderm Scop(R), 1999).


Other

3.3.16.A Withdrawal sign or symptom
1) Withdrawal symptoms consisting of dizziness, NAUSEA, VOMITING, HEADACHE, and disturbances of equilibrium have developed in a few patients following discontinuation of transdermal scopolamine. These symptoms have developed most often in patients who used the discs for more than 3 days (Prod Info Transdermal Scopolamine, 1998).

[Дядя_Федор]

Ну, психоз ему не грозит.
А вот херостомии я б на его месте опасался...